P-130 Latin American population with adenocarcinoma of the esophagogastric junction: A 9-year follow up

Esophagogastric junction (EGJ) adenocarcinoma represents 27% of gastric tumors with an increasing incidence in Western countries. Additionally, up to 80% EGJ are diagnosed advanced stages disease, therefore the prognosis is usually poor, a 5-year overall survival rate less than 30%. It known that entity its own epidemiological characteristics, biological behavior, and prognosis, without evidence support optimal management. The aim this study was describe clinicopathological features, treatment, outcome Latin American patients treated at National Cancer Institute. Retrospective, observational study. Included adenocarcinoma, Institute between 2003 2020. Statistical analysis required: X2 t test, Kaplan Meier, Log Rank Cox Regression. significance differences were assessed when p bilaterally <0.05. A total 174 included analysis. 82%(n=143) cases male median age diagnosis 58 (18-90) years old. Comorbidities type-2. Diabetes (21%), systemic arterial hypertension (20%), besides, almost half had history smoking alcohol consumption (45% 34%, respectively). Median disease pretreatment 4 months. Most prevalent symptoms weight loss (85%, n= 148), dysphagia (83%, 144), epigastric pain (47%, 6). Patients subdivided 2 groups 1) metastatic (n=80= non-metastatic (n=94). Among patients, (n=75) received neoadjuvant among them, 66% (n=62) chemoradiotherapy. Out who 82% (n=60) completed treatment 58% (n=34) them surgery, 59% (n=20) R0 surgical margins. An OS conducted comparing modalities these for chemoradiotherapy surgery median-OS 54 months versus 16 those complete (p=<0.001; HR 0.32, 95%CI 0.17-0.62). Otherwise (n=53) first-line chemotherapy remaining 34%(n=27) did not accept or candidates so best supportive care (BSC) decided. At analysis, 11 0.18, 0.09-0.36). Besides, clinical stage, 20 8 Non-metastatic 2.57, 1.75-3.79). Adenocarcinoma poor associated high prevalence gastroesophageal reflux, obesity, dietary changes. There no standard however, perioperative has shown benefit locally disease. As remains option. Further trials involving new therapy options necessary improve prognosis.